{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T07:26:07Z","timestamp":1777965967440,"version":"3.51.4"},"reference-count":57,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2004,9,1]],"date-time":"2004-09-01T00:00:00Z","timestamp":1093996800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Steroids"],"published-print":{"date-parts":[[2004,9]]},"DOI":"10.1016\/j.steroids.2004.05.015","type":"journal-article","created":{"date-parts":[[2004,9,21]],"date-time":"2004-09-21T18:24:21Z","timestamp":1095791061000},"page":"629-635","source":"Crossref","is-referenced-by-count":31,"title":["Toxicity and antineoplastic effect of (24R)-1,24-dihydroxyvitamin D3 (PRI-2191)"],"prefix":"10.1016","volume":"69","author":[{"given":"Joanna","family":"Wietrzyk","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marzena","family":"Pe\u0142czy\u0144ska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janusz","family":"Madej","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stanis\u0142aw","family":"Dzimira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Halina","family":"Ku\u015bnierczyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrzej","family":"Kutner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wies\u0142aw","family":"Szelejewski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam","family":"Opolski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.steroids.2004.05.015_bib1","first-page":"5217","article-title":"Antiproliferative activity in vitro of side-chain analogues of calcitriol against various human normal and cancer cell lines","volume":"19","author":"Opolski","year":"1999","journal-title":"Anticancer Res"},{"key":"10.1016\/j.steroids.2004.05.015_bib2","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1182\/blood.V92.7.2441","article-title":"19-Nor vitamin-D analogues: a new class of potent inhibitors of proliferation and inducers of differentiation of human myeloid leukaemia cell lines","volume":"92","author":"Asou","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.steroids.2004.05.015_bib3","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1006\/excr.1999.4475","article-title":"Role of vitamin D3 receptor in the synergistic differentiation of WEHI-3 leukemia cells by vitamin D3 and retinoic acid","volume":"249","author":"Li","year":"1999","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.steroids.2004.05.015_bib4","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1097\/00001813-199110000-00007","article-title":"Antitumor effect of 22-oxa-1alpha,25-dihydroxyvitamin D3, a potent angiogenesis inhibitor, on rat mammary tumors induced by 7,12-dimethylbenz[a]anthracene","volume":"2","author":"Oikawa","year":"1991","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.steroids.2004.05.015_bib5","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/0304-3835(94)03662-3","article-title":"Retinoids, interferon \u03b1, 1,25-dihydroxyvitamin D3 and their combination inhibit angiogenesis induced by non-HPV-harboring tumor cell lines. RAR\u03b1 mediates the antiangiogenic effect of retinoids","volume":"89","author":"Majewski","year":"1995","journal-title":"Cancer Lett"},{"key":"10.1016\/j.steroids.2004.05.015_bib6","series-title":"Vitamin D analogs in cancer prevention and therapy","first-page":"55","article-title":"Ligand structure\u2013function relationships in the vitamin D endocrine system from the perspective of drug development (including cancer treatment)","author":"Norman","year":"2003"},{"key":"10.1016\/j.steroids.2004.05.015_bib7","doi-asserted-by":"crossref","first-page":"755","DOI":"10.2174\/1381612003400407","article-title":"Biological activity in vitro of side-chain modified analogues of calcitriol","volume":"6","author":"Opolski","year":"2000","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.steroids.2004.05.015_bib8","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0960-0760(98)00065-X","article-title":"Cell differentiating and anti-proliferative activity of side-chain modified analogues of 1,25-dihydroxyvitamin D3","volume":"67","author":"Marcinkowska","year":"1998","journal-title":"J Steroid Biochem Mol Biol"},{"key":"10.1016\/j.steroids.2004.05.015_bib9","doi-asserted-by":"crossref","first-page":"410","DOI":"10.4161\/cc.1.6.269","article-title":"Derivatives of vitamins D2 and D3 activate three MAPK pathways and upregulate pRb expression in differentiating HL60 cells","volume":"1","author":"Ji","year":"2002","journal-title":"Cell Cycle"},{"key":"10.1016\/j.steroids.2004.05.015_bib10","doi-asserted-by":"crossref","first-page":"393","DOI":"10.18388\/abp.2002_3798","article-title":"Side-chain modified vitamin D analogs require activation of both PI 3-K and erk1, 2 signal transduction pathways to induce differentiation of human promyelocytic leukemia cells","volume":"49","author":"Marcinkowska","year":"2002","journal-title":"Acta Biochim Pol"},{"key":"10.1016\/j.steroids.2004.05.015_bib11","first-page":"83","article-title":"Vitamin D inhibits angiogenesis in transgenic murine retinoblastoma","volume":"36","author":"Shokravi","year":"1995","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.steroids.2004.05.015_bib12","first-page":"37","article-title":"Treating tumor-bearing mice with vitamin D3 diminishes tumor-induced myelopoiesis and associated immunosuppression, and reduces tumor metastasis and recurrence","volume":"41","author":"Young","year":"1995","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.steroids.2004.05.015_bib13","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/nrc1144","article-title":"Chemoprevention of colon cancer by calcium, vitamin D and folate: molecular mechanisms","volume":"3","author":"Lamprecht","year":"2003","journal-title":"Nat Rev Cancer"},{"issue":"7 Suppl","key":"10.1016\/j.steroids.2004.05.015_bib14","doi-asserted-by":"crossref","first-page":"2425S","DOI":"10.1093\/jn\/133.7.2425S","article-title":"Vitamin D-3 receptor as a target for breast cancer prevention","volume":"133","author":"Welsh","year":"2003","journal-title":"J Nutr"},{"key":"10.1016\/j.steroids.2004.05.015_bib15","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0027-5107(02)00341-X","article-title":"Chemoprevention of mammary carcinogenesis by 1alpha-hydroxyvitamin D5, a synthetic analog of Vitamin D","volume":"523\/524","author":"Mehta","year":"2003","journal-title":"Mutat Res"},{"key":"10.1016\/j.steroids.2004.05.015_bib16","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/978-3-642-55580-0_15","article-title":"The role of vitamin D in prostate cancer","volume":"164","author":"Krishnan","year":"2003","journal-title":"Recent Results Cancer Res"},{"key":"10.1016\/j.steroids.2004.05.015_bib17","first-page":"1339","article-title":"A phase I trial of calcitriol (1,25-dihydroxycalciferol) in patients with advanced malignancy","volume":"5","author":"Smith","year":"1999","journal-title":"Clin Cancer Res"},{"issue":"7 Suppl","key":"10.1016\/j.steroids.2004.05.015_bib18","doi-asserted-by":"crossref","first-page":"2461S","DOI":"10.1093\/jn\/133.7.2461S","article-title":"Pathways mediating the growth-inhibitory actions of vitamin D in prostate cancer","volume":"133","author":"Peehl","year":"2003","journal-title":"J Nutr"},{"key":"10.1016\/j.steroids.2004.05.015_bib19","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/sj.bjc.6601104","article-title":"A phase II study of the vitamin D analogue seocalcitol in patients with inoperable hepatocellular carcinoma","volume":"89","author":"Dalhoff","year":"2003","journal-title":"Br J Cancer"},{"key":"10.1016\/j.steroids.2004.05.015_bib20","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1067\/mcp.2002.129305","article-title":"Pharmacokinetics of high-dose oral calcitriol: results from a phase 1 trial of calcitriol and paclitaxel","volume":"72","author":"Muindi","year":"2002","journal-title":"Clin Pharmacol Ther"},{"issue":"4 Suppl 15","key":"10.1016\/j.steroids.2004.05.015_bib21","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0093-7754(01)90155-1","article-title":"Weekly high-dose calcitriol and docetaxel in advanced prostate cancer","volume":"28","author":"Beer","year":"2001","journal-title":"Semin Oncol"},{"key":"10.1016\/j.steroids.2004.05.015_bib22","first-page":"2848","article-title":"Combined effects of 1,25-dihydroxyvitamin D3 and platinum drugs on the growth of MCF-7 cells","volume":"51","author":"Cho","year":"1991","journal-title":"Cancer Res"},{"key":"10.1016\/j.steroids.2004.05.015_bib23","first-page":"862","article-title":"1,25-Dihydroxyvitamin D3 enhances the susceptibility of breast cancer cells to doxorubicin-induced oxidative damage","volume":"59","author":"Ravid","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/j.steroids.2004.05.015_bib24","first-page":"1925","article-title":"Potentiation of the antiproliferative effect in vitro of doxorubicin, cisplatin and genistein by new analogues of vitamin D","volume":"21","author":"Siwinska","year":"2001","journal-title":"Anticancer Res"},{"key":"10.1016\/j.steroids.2004.05.015_bib25","first-page":"200","article-title":"Structure\u2013function relationship in the vitamin D endocrine system","volume":"16","author":"Bouillon","year":"1995","journal-title":"Endocr Rev"},{"key":"10.1016\/j.steroids.2004.05.015_bib26","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1210\/endo-129-2-832","article-title":"A novel vitamin D3 analogue 22-oxa-1,25-dixydroxyvitamin D3, inhibits the growth of human breast cancer in vitro and in vivo without causing hypercalcemia","volume":"129","author":"Abe","year":"1991","journal-title":"Endocrinology"},{"key":"10.1016\/j.steroids.2004.05.015_bib27","first-page":"2534","article-title":"Antitumor effect of 22-oxa-calcitriol, a noncalcemic analogue of calcitriol, in athymic mice implanted with human breast carcinoma and its synergism with tamoxifen","volume":"53","author":"Abe-Hashimoto","year":"1993","journal-title":"Cancer Res"},{"key":"10.1016\/j.steroids.2004.05.015_bib28","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1002\/cncr.11179","article-title":"High-dose weekly oral calcitriol in patients with a rising PSA after prostatectomy or radiation for prostate carcinoma","volume":"97","author":"Beer","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.steroids.2004.05.015_bib29","series-title":"Vitamin D: biochemical, chemical and clinical aspects related to calcium metabolism","first-page":"587","article-title":"Serum and renal histologic changes in the rat following administration of toxic amounts of 1,25-dihydroxyvitamin D3","author":"Hartenbower","year":"1977"},{"key":"10.1016\/j.steroids.2004.05.015_bib30","first-page":"200","article-title":"Structure\u2013function relationship in the vitamin D endocrine system","volume":"16","author":"Bouillon","year":"1995","journal-title":"Endocr Rev"},{"key":"10.1016\/j.steroids.2004.05.015_bib31","doi-asserted-by":"crossref","first-page":"829","DOI":"10.2174\/138161200780574593","article-title":"Vitamin D analogs in cutaneous malignancies","volume":"6","author":"Majewski","year":"2000","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.steroids.2004.05.015_bib32","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1007\/BF02505274","article-title":"(1,24(OH)2D3, TV-02) inhibits phorbol ester-induced epidermal proliferation and cutaneous inflammation, and induces epidermal differentiation in mice","volume":"288","author":"Sato","year":"1996","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.steroids.2004.05.015_bib33","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1111\/j.1346-8138.1990.tb03015.x","article-title":"1 Alpha,24R-dihydroxyvitamin D3 has an ability comparable to that of 1 alpha, 25-dihydroxyvitamin D3 to induce keratinocyte differentiation","volume":"17","author":"Kobayashi","year":"1990","journal-title":"J Dermatol"},{"key":"10.1016\/j.steroids.2004.05.015_bib34","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1346-8138.1990.tb03714.x","article-title":"Effect of 1, 24R-dihydroxyvitamin D3 on the growth of human keratinocytes","volume":"17","author":"Matsumoto","year":"1990","journal-title":"J Dermatol"},{"key":"10.1016\/j.steroids.2004.05.015_bib35","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/j.1346-8138.1990.tb01614.x","article-title":"1,24(R)-Dihydroxyvitamin D3, a novel active form of vitamin D3 with high activity for inducing epidermal differentiation but decreased hypercalcemic activity","volume":"17","author":"Matsunaga","year":"1990","journal-title":"J Dermatol"},{"issue":"1","key":"10.1016\/j.steroids.2004.05.015_bib36","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0923-1811(02)00136-6","article-title":"Similarly potent action of 1,25-dihydroxyvitamin D3 and its analogues, tacalcitol, calcipotriol, and maxacalcitol on normal human keratinocyte proliferation and differentiation","volume":"31","author":"Takahashi","year":"2003","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.steroids.2004.05.015_bib37","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1185\/03007999809113361","article-title":"Current experience with tacalcitol ointment in the treatment of psoriasis","volume":"14","author":"Gollnick","year":"1998","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.steroids.2004.05.015_bib38","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/j.1365-2133.1997.tb03790.x","article-title":"Once daily treatment of psoriasis with tacalcitol compared with twice daily treatment with calcipotriol. A double-blind trial","volume":"137","author":"Veien","year":"1997","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.steroids.2004.05.015_bib39","doi-asserted-by":"crossref","first-page":"265","DOI":"10.2165\/00003495-199754020-00005","volume":"54","author":"Peters","year":"1997","journal-title":"Tacalcitol. Drugs"},{"key":"10.1016\/j.steroids.2004.05.015_bib40","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1080\/000155599750011309","article-title":"Proliferation is the main epidermal target in the treatment of psoriatic plaques with once daily application of tacalcitol ointment","volume":"79","author":"Castelijns","year":"1999","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.steroids.2004.05.015_bib41","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/S0039-128X(02)00038-7","article-title":"Synthesis and antiproliferative activity of side-chain unsaturated and homologated analogs of 1,25-dihydroxyvitamin D(2). (24E)-(1S)-24-Dehydro-24a-homo-1,25-dihydroxyergocalciferol and congeners","volume":"67","author":"Chody\u0144ski","year":"2002","journal-title":"Steroids"},{"key":"10.1016\/j.steroids.2004.05.015_bib42","unstructured":"Kutner A, Chody\u0144ski M, Szelejewski W, Odrzywolska M, Fitak H. Polish patent application no. P-324274. CA131:102429.1998."},{"key":"10.1016\/j.steroids.2004.05.015_bib43","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/nrc867","article-title":"Metastasis to bone: causes, consequences and therapeutic opportunities","volume":"2","author":"Mundy","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.steroids.2004.05.015_bib44","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1093\/jn\/131.11.2910","article-title":"The amino bisphosphonate ibandronate prevents vitamin D toxicity and inhibits vitamin D-induced calcification of arteries, cartilage, lungs and kidneys in rats","volume":"131","author":"Price","year":"2001","journal-title":"J Nutr"},{"key":"10.1016\/j.steroids.2004.05.015_bib45","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1023\/A:1024962316691","article-title":"Effects of seocalcitol (EB1089) on nitrosomethyl urea-induced rat mammary tumors","volume":"80","author":"Colston","year":"2003","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.steroids.2004.05.015_bib46","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/0010-4809(73)90033-5","article-title":"Generalized analysis of quantal dose\u2013response curves","volume":"6","author":"de Jong","year":"1973","journal-title":"Comput Biomed Res"},{"key":"10.1016\/j.steroids.2004.05.015_bib47","first-page":"577","article-title":"On biological assays involving quantal responses","volume":"183","author":"Waud","year":"1972","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.steroids.2004.05.015_bib48","series-title":"Manual of pharmacologic calculations, with computer programs","first-page":"153","article-title":"Procedure 46. Litchfield and Wilcoxon I: confidence limits of ED50, and Procedure 47. Litchfield and Wilcoxon II","author":"Tallarida","year":"1987"},{"key":"10.1016\/j.steroids.2004.05.015_bib49","first-page":"2673","article-title":"Two novel 14-Epi-analogues of 1,25-dihydroxyvitamin D3 inhibit the growth of human breast cancer cells in vitro and in vivo","volume":"60","author":"Verlinden","year":"2000","journal-title":"Cancer Res"},{"key":"10.1016\/j.steroids.2004.05.015_bib50","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1093\/jnci\/95.12.896","article-title":"Vitamin D2 analog 19-nor-1,25-dihydroxyvitamin D2: antitumor activity against leukemia, myeloma, and colon cancer cells","volume":"95","author":"Kumagai","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.steroids.2004.05.015_bib51","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1016\/S0968-0896(01)00159-6","article-title":"A non-calcemic sulfone version of the vitamin D(3) analogue seocalcitol (EB 1089): chemical synthesis, biological evaluation and potency enhancement of the anticancer drug adriamycin","volume":"9","author":"Posner","year":"2001","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.steroids.2004.05.015_bib52","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1182\/blood.V78.1.75.75","article-title":"Development of a novel 1,25(OH)2-vitamin D3 analog with potent ability to induce HL-60 cell differentiation without modulating calcium metabolism","volume":"78","author":"Zhou","year":"1991","journal-title":"Blood"},{"key":"10.1016\/j.steroids.2004.05.015_bib53","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1002\/(SICI)1097-4644(19970901)66:3<413::AID-JCB13>3.0.CO;2-F","article-title":"Vitamin D3 analogs and their 24-oxo metabolites equally inhibit clonal proliferation of a variety of cancer cells but have differing molecular effects","volume":"66","author":"Campbell","year":"1997","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.steroids.2004.05.015_bib54","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1001\/archopht.117.3.365","article-title":"Antineoplastic effect and toxicity of 1,25-dihydroxy-16-ene-23-yne-vitamin D3 in athymic mice with Y-79 human retinoblastoma tumors","volume":"117","author":"Sabet","year":"1999","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.steroids.2004.05.015_bib55","first-page":"1043","article-title":"Calcitriol (1,25-dihydroxycholecalciferol) enhances paclitaxel antitumor activity in vitro and in vivo and accelerates paclitaxel-induced apoptosis","volume":"7","author":"Hershberger","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.steroids.2004.05.015_bib56","first-page":"695","article-title":"1Alpha, 25dihydroxyvitamin D3 and platinum drugs act synergistically to inhibit the growth of prostate cancer cell lines","volume":"5","author":"Moffatt","year":"1999","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.steroids.2004.05.015_bib57","first-page":"247","article-title":"GABA level and GAD activity in human and mouse normal and neoplastic mammary gland","volume":"18","author":"Mazurkiewicz","year":"1999","journal-title":"J Exp Clin Cancer Res"}],"container-title":["Steroids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039128X04001436?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039128X04001436?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,3]],"date-time":"2020-04-03T05:30:29Z","timestamp":1585891829000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0039128X04001436"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,9]]},"references-count":57,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2004,9]]}},"alternative-id":["S0039128X04001436"],"URL":"https:\/\/doi.org\/10.1016\/j.steroids.2004.05.015","relation":{},"ISSN":["0039-128X"],"issn-type":[{"value":"0039-128X","type":"print"}],"subject":[],"published":{"date-parts":[[2004,9]]}}}